Minomic International Ltd has announced their MiCheck® Prostate test for detection of aggressive prostate cancer is now available at selected Sonic Healthcare Australia Pathology laboratories.
Minomic CEO Dr Brad Walsh says the availability of the test will help Australia’s urologists provide better patient care, stating that “the use of MRI …when combined with results from MiCheck® Prostate provide urologists with an additional aid in clinical decision-making before proceeding to more invasive investigations such as biopsy.”
With less than 50% of the 25,000 biopsies from Australian men each year, in response to an elevated Prostate-Specific Antigen (PSA) test, leading to a prostate cancer diagnosis, Minomic suggest more widespread use of MiCheck® could save unnecessary procedures.
This is a big win for one of our members, and for the tens of thousands of men screening for prostate cancer each year in Australia.